Top

Published in:

01-02-2012

Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases

Authors: Jens Sperling, Thilo Schäfer, Christian Ziemann, Anna Benz-Weißer, Otto Kollmar, Martin K. Schilling, Michael D. Menger

Published in: Clinical & Experimental Metastasis | Issue 2/2012

Abstract

Unresectable colorectal liver metastases are commonly treated with systemic chemotherapy (SCT). Clinical studies on the effect of additional systemic application of bevacizumab (BE), a monoclonal antibody directed against vascular endothelial growth factor, to SCT showed a slight increase of patient survival. Herein, we studied in a rat model of colorectal liver metastasis whether a locoregional application of oxaliplatin (OX) and BE via hepatic arterial infusion (HAI) is more effective to inhibit metastatic growth compared to systemic drug application. Ten days after implantation of CC531 colorectal cancer cells into the left liver lobe of WAG/Rij rats, animals underwent either HAI or systemic intravenous application of BE (5 mg/kg body weight), OX (85 mg/m² body surface) or a combination of both. Sham-treated animals received saline and served as controls. Tumor volume was measured at days 10 and 13 using three dimensional ultrasound. At day 13 tumor tissue was analyzed histologically and immunohistochemically. Systemic application of OX, BE or their combination did not affect tumor volume when compared to controls. In contrast, HAI of BE and particularly the combination of BE and OX significantly reduced tumor volume. In the tumor tissue this was associated with a decrease of vascularization and cell proliferation as well as an increase of cell apoptosis, as indicated by a decreased number of PECAM-1- and PCNA-positive cells and an increased number of cleaved caspase-3-positive cells. Locoregional administration of BE, particularly in combination with OX, enhances the inhibitory effect on hepatic metastatic growth compared to systemic application of the drugs.

Reinacher-Schick AC, Bechstein WO (2007) Colorectal liver metastases. Neoadjuvant chemotherapy: aspects of medical and surgical oncology. Internist 48:51–58PubMedCrossRef

Sperti E, Faggiuolo R, Gerbino A, Magnino A, Muratore A, Ortega C, Ferraris R et al (2006) Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach. Dis Colon Rectum 49:1596–1601PubMedCrossRef

Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30PubMedCrossRef

André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F, Beerblock K et al (1999) Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17:3560–3568PubMed

André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V et al (1999) CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35:1343–1347PubMedCrossRef

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMed

de Gramont A, Tournigand C, Louvet C, André T, Molitor JL, Raymond E, Moreau S et al (1997) Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD. Rev Med Interne 18:769–775PubMedCrossRef

Hebbar M, Tournigand C, Lledo G, Mabro M, André T, Louvet C, Aparicio T et al (2006) Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). Cancer Invest 24:154–159PubMedCrossRef

Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237PubMedCrossRef

10.

Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 24:394–400PubMedCrossRef

11.

Omura K (2008) Advances in chemotherapy against advanced or metastatic colorectal cancer. Digestion 77:13–22PubMedCrossRef

12.

Mocellin S, Pilati P, Lise M, Nitti D (2007) Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 25:5649–5654PubMedCrossRef

13.

Cohen AD, Kemeny NE (2003) An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8:553–566PubMedCrossRef

14.

Mocellin S, Pasquali S, Nitti D (2009) Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev, Issue 3. Art. No.: CD007823. doi:10.1002/14651858.CD007823.pub2

15.

United Kingdom Co-ordinating Committee on Cancer Research (1998) Guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77:1–10

16.

Benedict FG (1934) Die Oberflächenbestimmung verschiedener Tiergattungen [Determination of body surface area in different animal species]. Monatsschrift Kinderheilkunde 36:300–346

17.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D et al (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 13:1845–1857PubMedCrossRef

18.

Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545–2552PubMedCrossRef

19.

Heiduschka P, Julien S, Hofmeister S, Bartz-Schmidt KU, Schraermeyer U (2008) Bevacizumab (avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina 28:46–55PubMedCrossRef

20.

Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU et al (2008) Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol 86:322–328PubMedCrossRef

21.

Barros LF, Belfort R (2007) The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 79:389–394PubMedCrossRef

22.

Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, Rosner M (2010) The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol 88:862–867PubMedCrossRef

23.

Hashemian MN, Moghimi S, Kiumehr S, Riazi M, Amoli FA (2009) Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats. Ophthalmic Res 42:90–95PubMedCrossRef

24.

Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F (2007) Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 35:745–748PubMedCrossRef

25.

Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC et al (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91:804–807PubMedCrossRef

26.

Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA (2008) Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 145:424–431PubMedCrossRef

27.

Oh JY, Kim MK, Shin MS, Lee HJ, Lee JH, Wee WR (2009) The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res 34:85–91PubMedCrossRef

28.

Abcouwer SF, Lin CM, Wolpert EB, Shanmugam S, Schaefer EW, Freeman WM, Barber AJ et al (2010) Vascular permeability and apoptosis are separable processes in retinal ischemia-reperfusion injury: effects of ischemic preconditioning, bevacizumab and etanercept. Invest Ophthalmol Vis Sci. Epub ahead of print

29.

Kim EC, Lee WS, Kim MS (2010) The inhibitory effects of bevacizumab eyedrops on NGF expression and corneal wound healing in rats. Invest Ophthalmol Vis Sci 51:4569–4573PubMedCrossRef

30.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRef

31.

Mac Gabhann F, Popel AS (2008) Systems biology of vascular endothelial growth factors. Microcirculation 15:715–738PubMedCrossRef

32.

Roy H, Bhardwaj S, Yla-Herttuala S (2006) Biology of vascular endothelial growth factors. FEBS Lett 580:2879–2887PubMedCrossRef

33.

Fernando NH, Hurwitz HI (2003) Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 30:39–50PubMed

34.

Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789–1797PubMedCrossRef

35.

Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850PubMed

36.

Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65PubMedCrossRef

37.

Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544PubMedCrossRef

38.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef

39.

de Gramont A, Tournigand C, Andre T, Larsen AK, Louvet C (2006) Targeted agents for adjuvant therapy of colon cancer. Semin Oncol 33:42–45CrossRef

40.

Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557–4561PubMedCrossRef

41.

Goldberg RM, Hurwitz HI, Fuchs CS (2006) The role of targeted therapy in the treatment of colorectal cancer. Clin Adv Hematol Oncol 4(1–10):11–12

42.

Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM et al (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24:769–777PubMedCrossRef

43.

Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, Mainwaring P et al (2009) Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77:113–119PubMedCrossRef

44.

Iqbal S, Lenz HJ (2004) Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol 54(Suppl 1):S32–S39PubMed

45.

Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S (2009) Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev 8:CD005392

46.

Fernando NH, Hurwitz HI (2004) Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9:11–18PubMedCrossRef

47.

Yang H, Jager MJ, Grossniklaus HE (2010) Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci 51(6):2835–2842PubMedCrossRef

48.

Breedis C, Young C (1954) The blood supply of neoplasms in the liver. Am J Pathol 30:969–985PubMed

49.

Burkel WE (1970) The fine structure of the terminal branches of the hepatic arterial system of the rat. Anat Rec 167:329–349PubMedCrossRef

50.

Gonda T, Ishida H, Yoshinaga K, Sugihara K (2000) Microvasculature of small liver metastases in rats. J Surg Res 94:43–48PubMedCrossRef

51.

Okuno K, Hirai N, Lee YS, Tarabar D, Ueno H, Yasutomi M et al (1998) Superiority of hepatic arterial infusion in preventing catabolism of 5-FU compared with portal vein infusion revealed by an in vivo 19F NMR study. Cancer Chemother Pharmacol 42:341–344PubMedCrossRef

52.

Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL et al (2004) Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 15:467–473PubMedCrossRef

53.

Cusack JC Jr, Liu R, Xia L, Chao TH, Pien C, Niu W, Palombella VJ et al (2006) NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 12:6758–6764PubMedCrossRef

Title: Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases
Authors: Jens Sperling
Thilo Schäfer
Christian Ziemann
Anna Benz-Weißer
Otto Kollmar
Martin K. Schilling
Michael D. Menger
Publication date: 01-02-2012
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 2/2012
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-011-9432-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-κB/AP-1 dependent- and independent-signaling

Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease

CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer

Alteration of bone sialoprotein expression in osseous metastasized renal cell carcinomas and the tumor surrounding tissue

Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis

Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer